Harmonised relative effectiveness discussions moving ahead in Europe
This article was originally published in SRA
Executive Summary
Support for a single European relative effectiveness assessment conducted by the European Medicines Agency is gaining momentum with the pharmaceutical industry, said Andrew Witty, president of the European pharmaceutical industry federation, EFPIA, at a press conference for its annual meeting in London, 21-22 June1.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.